<DOC>
	<DOC>NCT02788240</DOC>
	<brief_summary>All consecutive ACLF (Acute on Chronic Liver failure) patients presenting to the institute of liver and biliary sciences, irrespective of the etiology , who have survived the acute phase (i.e. 90 days of onset of the acute on chronic liver failure) and who are willing to participate in the study would be enrolled. After performing baseline biochemical tests, patients will undergo transjugular liver biopsy (TJLB), HVPG (Hepatic Venous Pressure Gradient), Circulating CD34 cells, Bone marrow aspiration and biopsy (Histopathological and immunohistochemical examination will be done).</brief_summary>
	<brief_title>To Study the Influence of GCSF on Natural History of Acute On Chronic Liver Failure After the Acute Phase</brief_title>
	<detailed_description />
	<mesh_term>Liver Failure</mesh_term>
	<mesh_term>End Stage Liver Disease</mesh_term>
	<mesh_term>Acute-On-Chronic Liver Failure</mesh_term>
	<mesh_term>Meropenem</mesh_term>
	<mesh_term>Terlipressin</mesh_term>
	<criteria>Subjects aged 1865 years All patients who were known to have ACLF and have survived 3 months of the onset of acute event Patients willing to participate in the study Presence of AKI (Acute Kidney Injury) Active sepsis (Blood/ urine culture positive, SBP (Spontaneous bacterial Peritonitis, LRTI (lower Respiratory Tract infection) Sickle cell anemia HepatoCellular Carcinoma Hematological malignancies Multi organ failure Grade 3/ 4 HE (Hepatic Encephalopathy) HIV seropositivity Pregnancy Patients being taken up for transplant Refusal to participate in the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>